Diego Villa, MD, MPH, discusses the rationale for a retrospective analysis evaluating bendamustine plus rituximab as induction therapy in patients with mantle cell lymphoma.
Diego Villa, MD, MPH, clinical associate professor in the Division of Medical Oncology of the Department of Medicine at The University of British Columbia, discusses the rationale for a retrospective analysis evaluating bendamustine plus rituximab(Rituxan; BR) as induction therapy in patients with mantle cell lymphoma (MCL).
The rationale for a retrospective analysis conducted at The University of British Columbia came from the phase 3 STiL-1 trial, in which the combination demonstrated excellent response rates and progression-free survival compared with the previous standard, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), says Villa.
However, it is important to note that STiL-1 was done in transplant-ineligible patients. The question of whether to use BR in transplant-eligible patients was still unknown. Other advantages to BR include that it does not cause alopecia or severe nausea, vomiting, or peripheral neuropathy associated with R-CHOP, concludes Villa.